Pharmacological interventions to prevent vascular endothelial dysfunction: Future directions

Journal of Health Science

Volumn 54, Issue 1, 2008, Pages 1-16

  Balakumar, Pitchai ^a   Koladiya, Rajeshkumar U ^b   Ramasamy, Subbiah ^c   Rathinavel, Andiappan ^d   Singh, Manjeet ^a  

^a ISF Institute of Pharmaceutical Sciences and Drug Research   (India)

^b PUNJABI UNIVERSITY   (India)

^c MADURAI KAMARAJ UNIVERSITY   (India)

^d MADURAI MEDICAL COLLEGE   (India)

Author keywords

Angiotensin converting enzyme inhibitor; Endothelial dysfunction; Insulin sensitizer; L arginine; Novel target site; Statin

Indexed keywords

AMLODIPINE; ANTIOXIDANT; ARGININE; ATORVASTATIN; AZELNIDIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; FOLIC ACID; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LISINOPRIL; MEVINOLIN; NIFEDIPINE; OLMESARTAN; PERINDOPRIL; PITAVASTATIN; PRAVASTATIN; QUINAPRIL; RAMIPRIL; SIMVASTATIN; SITAXSENTAN; TETRAHYDROBIOPTERIN; TROGLITAZONE; UNINDEXED DRUG; ZOFENOPRIL;

ATHEROSCLEROSIS; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FAILURE; LEUKOCYTE ADHERENCE; LIVER TOXICITY; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; SHORT SURVEY; SMOOTH MUSCLE FIBER; STROKE; SYNTHESIS; THROMBOCYTE AGGREGATION; VASODILATATION;

EID: 44449158575     PISSN: 13449702     EISSN: 13475207     Source Type: Journal    
DOI: 10.1248/jhs.54.1     Document Type: Short Survey

References (160)

1. Nedeljkovic, Z. S., Gokce, N. and Loscalzo, J. (2003) Mechanisms of oxidative stress and vascular dysfunction. Postgrad. Med. J., 79, 195-200.
2. Davignon, J. and Ganz, P. (2004) Role of Endothelial Dysfunction in Atherosclerosis. Circulation, 109, 27-32.
3. Willerson, J. T. and Kereiakes, D. J. (2003) Endothelial dysfunction. Circulation, 108, 2060-2061.
4. Bian, K. and Murad, F. (2007) Nitric oxide signaling in vascular biology. J. Am. Soc. Hypertens., 1, 17-29.
5. Ferroni, P., Basili, S., Paoletti, V. and Dav?, G. (2006) Endothelial dysfunction and oxidative stress in arterial hypertension. Nutr. Metab. Cardiovasc. Dis., 16, 222-233.
6. Endemann, D. H. and Schiffrin, E. L. (2004) Endothelial dysfunction. J. Am. Soc. Nephrol., 15, 1983-1992.
7. Cybulsky, M. I. and Gimbrone, M. A. Jr. (1991) Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science, 4, 53-65.
8. Wolfrum, S., Jensen, K. S. and Liao, J. K. (2003) Endothelium-Dependent Effects of Statins. Arterioscler. Thromb. Vasc. Biol., 23, 729-736.
9. Nadar, S., Blann A. D. and Lip, G. Y. (2004) Endothelial dysfunction: methods of assessment and application to hypertension. Curr. Pharm. Des., 10, 3591-3605.
10. Ignarro, L. J., Buga, G. M., Wood, K. S., Byrns, R. E. and Chaudhuri, G. (1987) Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A., 84, 9265-9269.
11. Esper, R. J., Roberto A Nordaby, R, A., Vilariño, J, O., Antonio Paragano, A., Cacharrón, J. L. and Machado, R. A. (2006) Endothelial dysfunction: a comprehensive appraisal. Cardiovasc. Diabetol., 5, 1-18.
12. Yetik-Anacak, G. and Catravas, J. D. (2006) Nitric oxide and the endothelium: History and impact on cardiovascular disease. Vascul. Pharmacol., 45, 268-276.
13. Khachigian, L. M. (2004) Oxidative Stress and Endothelial Dysfunction. Endothelium, 11, 77-78.
14. Wassmann, S. and Nickenig, G. (2003) Interrelationship of Free Oxygen Radicals and Endothelial Dysfunction-Modulation by Statins. Endothelium, 10, 23-33.
15. Papaharalambus, C. A. and Griendling, K. K. (2007) Basic Mechanisms of Oxidative Stress and Reactive Oxygen Species in Cardiovascular Injury. Trends. Cardiovasc. Med., 17, 48-54.
16. Forstermann, U. and Munzel, T. (2006) Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation, 113, 1708-1714.
17. Woo, K. S., Sanderson, J. E., Sun, Y. Y., Chook, P., Cheung, A. S. P., Chan, L. T., Metreweli, C., Lolin, Y. I. and Celermajer, D. S. (2000) Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation, 101(12): e116-116.
18. Bonetti, P. O., Lerman, L. and Lerman, A. (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol., 23, 168-175.
19. Avogaro, A. and Vigili de Kreutzenberg, S. V. (2005) Mechanisms of endothelial dysfunction in obesity. Clin. Chim. Acta, 360, 9-26.
20. Balakumar, P., Jindal, S., Shah, D. I. and Singh, M. (2007a) Experimental models for vascular endothelial dysfunction. Trends in Medical Research, 2, 12-20.
21. Balakumar, P., Jindal, S. and Singh, M. (2007b) Novel use of uric acid and sodium arsenite to induce vascular endothelial dysfunction in rats. Journal of Pharmacology and Toxicology, 2, 437-446.
22. Jindal, S., Singh, M. and Balakumar, P. (2007) Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int. J. Cardiol. (doi:10.1016/j.ijcard.2007.05.031) .
23. Bush, D. E., Jones, C. E., Bass, K. M., Walters, G. K., Bruza, J. M. and Ouyang, P. (1998) Estrogen Replacement Reverses Endothelial Dysfunction in Postmenopausal Women. Am. J. Med., 104, 552-558.
24. Al-Shaer, M. H., Choueiri, N. E., Correia, M. L. G., Sinkey, C. A., Barenz, T. A. and Haynes, W. G. (2006) Effects of aging and atherosclerosis on endothelial and vascular smooth muscle function in humans. Int. J. Cardiol., 109, 201-206.
25. Puranik, R. and Celermajer, D. S. (2003) Smoking and Endothelial Function. Prog. Cardiovasc. Dis., 45, 443-458.
26. Luscher, T. F. and Vanhoutte, P. M. (1987) Endothelium dependent vascular response in normotensive and hypertensive Dahl rats. Hypertension, 9, 157-163.
27. Thambyrajah, J., Landray, M. J., Jones, H. J., McGlynn, F. J., Wheeler, D. C. and Townend, J. N. (2001) A Randomized Double-Blind Placebo-Controlled Trial of the Effect of Homocysteine-Lowering Therapy with Folic Acid on Endothelial Function in Patients with Coronary Artery Disease. J. Am. Coll. Cardiol., 37, 1858-1863.
28. Schafer, A., Fraccarollo, D., Tas, P., Schmidt, I., Ertl, G. and Bauersachsa, J. (2004) Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism. Eur. J. Heart Fail., 6, 151-159.
29. De Vriese, A. S., Verbeuren, T. J., van de Voorde, J., Lameire, N. H. and Vanhoutte, P. M. (2003) Endothelial dysfunction in diabetes. Br. J. Pharmacol., 130, 963-974.
30. Faraci, F. M. and Lentz, S. R. (2004). Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke, 35, 345-347.
31. Rallidis, L. S., Lekakis, J. and Kremastinos, D. T. (2007) Current questions regarding the use of statins in patients with coronary heart disease. Int. J. Cardiol., 122, 188-194.
32. Böhm, M. (2007) Angiotensin Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors: Where Do We Stand Now? Am. J. Cardiol., 100, 38J-44J.
33. Sfikakis, P. P., Papamichael, C., Stamatelopoulos, K. S., Tousoulis, D., Fragiadaki, K. G., Katsichti, P., Stefanadis, C. and Mavrikakis, M. (2007) Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum., 56, 1985-1993.
34. Barst, R. J., Langleben, D., Badesch, D., Frost, A., Lawrence, E. C., Shapiro, S. Naeije, R. and Galie, N. (2006) Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist Sitaxsentan. J. Am. Coll. Cardiol., 47, 2049-2056.
35. Barton, M. (2000) Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics. Curr. Hypertens. Rep., 2, 84-91.
36. Koh, K. K., Quon, M. J., Lee, S. J., Han, S. H., Ahn, J. Y., Kim, J., Chung, W., Lee, Y. and Shin, E. K. (2007) Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in nondiabetic patients with hypertension. Diabetes Care, 30, 1605-1607.
37. Suzuki, M., Takamisawa, I., Yoshimasa, Y. and Harano, Y. (2007) Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. Diabetes Res. Clin. Pract., 76, 12-17.
38. Bahia, L., Aguiar, L. G. K., Villela, N., Bottino, D., Godoy-Matos, A. F., Geloneze, B., Tambascia, M. and Bouskela, E. (2007) Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome. Atherosclerosis, 195, 138-146.
39. Praticò, D. (2005) Antioxidants and endothelium protection. Atherosclerosis, 181, 215-224.
40. Lim, D. S., Mooradian, S. J., Goldberg, C. S., Gomez, C., Crowley, D. C., Rocchini, A. P. and Charpie, J. R. (2004) Effect of oral L-arginine on oxidant stress, endothelial dysfunction, and systemic arterial pressure in young cardiac transplant recipients. Am. J. Cardiol., 94, 828-831.
41. Wang, X., Hattori, Y., Satoh, H., Iwata, C., Banba, N., Monden, T., Uchida, K., Kamikawa, Y. and Kasai, K. (2007) Tetrahydrobiopterin prevents endothelial dysfunction and restores adiponectin levels in rats. Eur. J. Pharmacol., 555, 48-53.
42. Moat, S. J., Lang, D., McDowell, L. F. W., Clarke, Z. L., Madhavan, A. K., Lewis, M. J. and Goodfellow, J. (2004) Folate, homocysteine, endothelial function and cardiovascular disease. J. Nutr. Biochem., 15, 64-79.
43. Wassmann, S., Laufs, U., Baumer, A. T., Müller, K., Ahlbory, K., Wolfgang Linz, W., Itter, G., Rösen, R., Böhm, M. and Nickenig, G. (2001) HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension, 37, 1450-1457.
44. Järvisalo, M. J., Toikka, J. O., Vasankari, T., Mikkola, J., Viikari, J. S. A., Hartiala, J. J. and Raitakari, O. T. (1999) HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis, 147, 237-242.
45. Briel, M., Schwartz, G. G., Thompson, P. L., de Lemos, J. A., Blazing, M. A., van Es, G. A., Kayikcioglu, M., Arntz, H. R., den Hartog, F. R., Veeger, N. J., Colivicchi, F., Dupuis, J., Okazaki, S., Wright, R. S., Bucher, H. C. and Nordmann A. J. (2006) Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes:Ameta-analysis of randomized controlled trials. J. Am. Med. Assoc., 295, 2046-2056.
46. Li, D. and Mehta, J. L. (2003) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect against oxidized low-density lipoprotein-induced endothelial dysfunction. Endothelium, 10, 17-21.
47. Wassmann, S., Faul, A., Hennen, B., Scheller, B., Bohm, M. and Nickenig, G. (2003) Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ. Res., 93, e98-e103.
48. Tousoulis, D., Antoniades, C., Katsi, V., Bosinakou, E., Kotsopoulou, M., Tsioufis, C. and Stefanadis, C. (2006) The impact of early administration of lowdose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level. Int. J. Cardiol., 109, 48-52.
49. Lindholm, M. W. and Nilsson, J. (2007) Simvastatin stimulates macrophage interleukin-1β secretion through an isoprenylation-dependent mechanism. Vascul. Pharmacol., 46, 91-96.
50. Laufs, U., La Fata, V., Plutzky, J. and Liao, J. K. (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 97, 1129-1135.
51. Von Haehling, S., Anker, S. D. and Bassenge, E. (2003) Statins and the role of nitric oxide in chronic heart failure. Heart Fail. Rev., 8, 99-106.
52. Kureishi, Y., Luo, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D. J., Sessa, W. C. and Walsh, K. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med., 6, 1004-1010.
53. Goldstein, J. L. and Brown, M. S. (1990) Regulation of the mevalonate pathway. Nature, 343, 425-430.
54. Hernandez-Perera, O., Perez-Sala, D., Navarro-Antolin, J., Sanchez-Pascuala, R., Hernandez, G. and Diaz, C. (1998) Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest., 101, 2711-2719.
55. Sakabe, K., Fukuda, N., Fukuda, Y., Wakayama, K., Nada, T., Morishita, S., Shinohara, H. and Tamura, Y. (2007) Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int. J. Cardiol. (doi:10.1016/j.ijcard.2007.01.040).
56. Anderson, T. J., Meredith, I. T., Yeung, A. C., Frei, B., Selwyn, A. P. and Ganz, P. (1995) The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med., 332, 488-493.
57. Perticone, F., Ceravolo, R., Maio, R., Cloro, C., Candigliota, M., Scozzafava, A., Mongiardo, A., Mastroroberto, P., Chello, M. and Mattioli, P. L. (2000) Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. Atherosclerosis, 152, 511-518.
58. Wassmann, S., Ribaudo, N., Faul, A., Laufs, U., Bohm, M. and Nickenig, G. (2004) Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels 130 mg/dl. Am. J. Cardiol., 93, 84-88.
59. Mercuro, G., Zoncu, S., Saiu, F., Sarais, C. and Rosano, G. M. (2002) Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels. Am. J. Cardiol., 90, 747-750.
60. John, S., Delles, C., Jacobi, J., Schlaich, M. P., Schneider, M., Schmitz, G. and Schmieder, R. E. (2001). Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J. Am. Coll. Cardiol., 37, 1351-1358.
61. Treasure, C. B., Klein, J. L., Weintraub, W. S., Talley, J. D., Stillabower, M. E., Kosinski, A. S., Zhang, J., Boccuzzi, S. J., Cedarholm, J. C. and Alexander, R. W. (1995) Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med., 332, 481-487.
62. Dupuis, J., Tardif, J. C., Cernacek, P. and Theroux, P. (1999) Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation, 99, 3227-3233.
63. Penny, W. F., Ben Yehuda, O., Kuroe, K., Long, J., Bond, A., Bhargava, V., Peterson, J. F., McDaniel, M., Juliano, J., Witztum, J. L., Ross J. Jr. and Peterson, K. L. (2001) Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J. Am. Coll. Cardiol., 37, 766-774.
64. Laufs, U., Wassmann, S., Hilgers, S., Ribaudo, N., Bohm, M. and Nickenig, G. (2001) Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am. J. Cardiol., 88, 1306-1307.
65. Van de Ree, M. A., Huisman, M. V., de Man, F. H., van der Vijver, J. C., Meinders, A. E. and Blauw, G. J. (2001) Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc. Res., 52, 299-305.
66. Fenster, B. E., Tsao, P. S. and Rockson, S. G. (2003) Endothelial dysfunction: Clinical strategies for treating oxidant stress. Am. Heart J., 146, 218-226.
67. Rajagopalan, S., Kurz, S., Munzel, T., Tarpey, M., Freeman, B., Griendling, K. and Harrison, D. (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest., 97, 1916-1923.
68. Hornig, B., Kohler, C. and Drexler, H. (1997) Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation, 95, 1115-1118.
69. Yu, W., Akishita, M., Xi, H., Nagai, K., Sudoh, N., Hasegawa, H., Kozaki, K. and Toba, K. (2006) Angiotensin converting enzyme inhibitor attenuates oxidative stress-induced endothelial cell apoptosis via p38 MAP kinase inhibition. Clin. Chim. Acta, 364, 328-334.
70. Kovacs, I., Toth, J., Tarjan, J. and Koller, A. (2006) Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE. Eur. J. Heart Fail., 8, 451-459.
71. Scribnera, A. W., Loscalzoa, J. and Napoli, C. (2003) The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur. J. Pharmacol., 482, 95-99.
72. Wassmann, K., Ghiassi, A., Wassmann, S., Bo"hm, M. and Nickenig, G. (2006) AT1 receptor antagonism improves endothelial dysfunction in postmenopausal women. Maturitas, 53, 176-183.
73. Warnholtz, A., Ostad, M. A., Heitzer, T., Thuneke, F., Fröhlich, M., Tschentscher, P., Schwedhelmd, E., Böger, R., Meinertz, T. and Munzel, T. (2006) AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. Atherosclerosis, 194, 439-445.
74. Colonnaa, V. D. G., Rigamontia, A., Fiorettia, S., Bonomoa, S., Manfredia, B., Ferrarioa, P., Bianchia, M., Bertia, F., Mullera, E. E. and Rossonib, G. (2005) Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in l-NAME-induced hypertensive rats. Eur. J. Pharmacol., 51, 6253-6259.
75. Mancini, G. B., Henry, G. C., Macaya, C., O'Neill, B. J., Pucillo, A. L., Carere, R. G., Wargovich, T. J., Mudra, H., Luscher, T. F., Klibaner, M. I., Haber, H. E., Uprichard, A. C., Pepine, C. J. and Pitt, B. (1996) Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation, 94, 258-265.
76. O'Driscoll, G., Green, D. and Taylor, R. R. (1997) Simvastatin, an HMGcoenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation, 95, 1126-1131.
77. Mullen, M. J., Clarkson, P., Donald, A. E., Thomson, H., Thorne, S. A., Powe, A. J., Furuno, T., Bull, T. and Deanfield, J. E. (1998) Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomized, double-blind study. J. Am. Coll. Cardiol., 31, 1330-1335.
78. O'Driscoll, G., Green, D., Maiorana, A., Stanton, K., Colreavy, F. and Taylor, R. (1999) Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol., 33, 1506-1511.
79. Wilmink, H. W., Banga, J. D., Hijmering, M., Erkelens, W. D., Stroes, E. S. and Rabelink, T. J. (1999) Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function. J. Am. Coll. Cardiol., 34, 140-145.
80. McFarlane, R., McCredie, R. J., Bonney, M. A., Molyneaux, L., Zilkens, R., Celermajer, D. S. and Yue, D. K. (1999). Angiotensin converting enzyme inhibition and arterial endothelial function in adults with Type 1 diabetes mellitus. Diabet. Med., 16, 62-66.
81. Esper, R. J., Machado, R., Vilarino, J., Cacharron, J. L., Ingino, C. A., García Guiñazú, C. A., Bereziuk, E., Bolano, A. L. and Suarez, D. H. (2000) Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined. Am. Heart J., 140, 684-689.
82. Bae, J. H., Bassenge, E., Lee, H. J., Park, K. R., Park, C. G., Park, K. Y., Lee, M. S. and Schwemmer, M. (2001) Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates. Atherosclerosis, 158, 165-171.
83. Pasini, A. F., Garbin, U., Nava, M. C., Stranieri, C., Pellegrini, M., Boccioletti, V., Luchetta, M. L., Fabrizzi, P., Cascio, V. L. and Cominacini, L. (2007) Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am. J. Hypertens., 20, 443-450.
84. Best, P. J. M., Lerman, L. O., Romero, J. C, Richardson, D., Holmes, D. R. and Lerman, A. (1999) Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia in vitro. Arterioscler Thromb Vasc Biol., 19, 2769-2775.
85. Barton, M., Haudenschild, C. C., d'Uscio, L. V., Shaw, S., Münter, K. and Lu scher, T. F. (1998) Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U.S.A., 95, 14367-14372.
86. Halcox, J. P. J., Nour, K. R. A., Zalos, G. and Quyyumi, A. A. (2001) Coronary vasodilation and improvement in endothelial dysfunction with endothelin ETA receptor blockade. Circ. Res., 89, 969-976.
87. Böhm, F., Beltran, E. and Pernow, J. (2005) Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition. J. Intern. Med., 257, 263-271.
88. Dupuis, J. (2007). Endothelin: setting the scene in PAH. Eur. Respir. Rev., 16, 3-7.
89. Wenzel, R. R., Fleisch, M., Shaw, S., Noll, G., Kaufmann, U., Schmitt, R., Jones, C. R., Clozel, M., Meier, B. and Lüscher, T. F. (1998) Haemodynamic and coronay effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation, 98, 2235-2240.
90. D'Alto, M., Vizza, C. D., Romeo, E., Badagliacca, R., Santoro, G., Poscia, R., Sarubbi, B., Mancone, M., Argiento, P., Ferrante, F., Russo, M. G., Fedele, F. and Calabrò, R. (2007) Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart, 93, 621-625.
91. Asano, Y., Kim, J., Ogai, A., Takashima, S., Shintani, Y., Minamino, T., Kitamura S., Tomoike, H., Hori, M. and Kitakaze, M. (2003) A calcium channel blocker activates both ecto-50-nucleotidase and NO synthase in HUVEC. Biochem. Biophys. Res. Commun., 311, 625-628.
92. Batova, S., De Wever, J., Godfraind, T., Balligand, J. L., Dessy, C. and Feron, O. (2006) The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovasc. Res., 71, 478-485.
93. Matsubara, M., Yao, K. and Hasegawa, K. (2006) Benidipine, a dihydropyridine-calcium channel blocker, inhibits lysophosphatidylcholine- induced endothelial injury via stimulation of nitric oxide release. Pharmacol. Res., 53, 35-43.
94. Naito, Y., Shimozawa, M., Manabe, H., Nakabe, N., Katada, K., Kokura, S., Yoshida, N., Ichikawa, H., Kon, T. and Yoshikawa, T. (2006) Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur. J. Pharmacol., 546, 11-18.
95. Verhaar, M. C., Honing, M. L., van Dam, T., Zwart, M., Koomans, H. A., Kastelein, J. J. and Rabelink, T. J. (1999) Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc. Res., 42, 752-760.
96. Naya, M., Tsukamoto, T., Morita, K., Katoh, C., Furumoto, T., Fujii, S., Tamaki, N. and Tsutsui, H. (2007) Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J. Am. Coll. Cardiol., 50, 1144-1149.
97. Saltiel, A. R. and Olefsky, J. M. (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 45, 1661-1669.
98. Sheu, W. H., Ou, H. C., Chou, F. P., Lin, T. M. and Yang, C. H. (2006) Rosiglitazone inhibits endothelial proliferation and angiogenesis. Life Sci., 78, 1520-1528.
99. Hennuyer, N., Poulain, P., Madsen, L., Berge, R. K., Houdebine, L. M., Branellec, D., Fruchart, J. C., Fievet, C., Duverger, N. and Staels, B. (1999) Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. Circulation, 99, 2445-2451.
100. Sheu, W. H., Ou, H., Chou, F., Lin, T. and Yang, C. (2006) Rosiglitazone inhibits endothelial proliferation and angiogenesis. Life Sci., 78, 1520-1528.
101. Gensch, C., Clever, Y. P., Werner, C., Hanhoun, M., Böhm, M. and Laufs, U. (2007) The PPARgamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis, 192, 67-74.
102. Bruemmer, D., Blaschke, F. and Law, R. E. (2005) New targets for PPARgamma in the vessel wall: implications for restenosis. Int. J. Obes., 29, S26-S30.
103. Calnek, D. S., Mazzella, L., Roser, S., Roman, J. and Hart, C. M. (2003) Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol., 23, 52-57.
104. Tousoulis, D., Xenakis, C., Tentolouris, C., Davies, G., Antoniades, C., Crake, T. and Stefanadis, C. (2005) Effects of vitamin C on intracoronary L-arginine dependent coronary vasodilatation in patients with stable angina. Heart, 91, 1319-1323.
105. Boger, R. H. (2006) Asymmetric dimethylarginine (ADMA): Anovel risk marker in cardiovascular medicine and beyond. Ann. Med., 38, 126-136.
106. Maxwell, A. J. and Cooke, J. P. (1998) Cardiovascular effects of L-arginine. Curr. Opin. Nephrol. Hypertens., 7, 63-70.
107. Goumas, G., Tentolouris, C., Tousoulis, D., Stefanadis, C. and Toutouzas, P. (2001) Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis, 154, 255-267.
108. Maxwell, A. J., Anderson, B., Zapien, M. P. and Cooke, J. P. (2000) Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity. Cardiovasc. Drugs Ther., 14, 309-316.
109. Wolf, A., Zalpour, C., Theilmeier, G., Bing-Yin, W., Ma, A., Anderson, B., Tsao, P. S. and Cooke, J. P. (1997) Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J. Am. Coll. Cardiol., 29, 479-485.
110. Theilmeier, G., Chan, J. R., Zalpour, C., Anderson, B., Wang, B. Y., Wolf, A., Tsao, P. S. and Cooke, J. P. (1997) Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary Larginine. Arterioscler. Thromb. Vasc. Biol., 17, 3557-3564.
111. Sydow, K., Schwedhelm, E., Arakawa, N., Bode-Böger, S. M., Tsikas, D., Hornig, B., Frölich, J. C. and Böger, R. H. (2003) A DMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc. Res., 57, 244-252.
112. Nakai, Y., Voisine, P., Bianchi, C., Xu, S., Feng, J., Malik, T., Rosinberg, A. and Sellke, F. W. (2005) Effectsof L-arginine on the endogenous angiogenic response in a model of hypercholesterolemia. Surgery, 138, 291-298.
113. Bath, P. M. W., Willmot, M., Leonardi-Bee, J. and Bath-Hextall, F. J. (2000) Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke. The Cochrane Database of Systematic Reviews, CD000398, 1-18.
114. Kaufman, S. (1993) New tetrahydrobiopterin-dependent systems. Annu. Rev. Nutr., 13, 261-286.
115. Harrison, D. G. (1997) Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest., 100, 2153-2157.
116. Higashi, Y., Sasaki, S., Nakagawa, K., Kimura, M., Noma, K., Hara, K., Jitsuiki, D., Goto, C., Oshimac, T., Chayama, K. and Yoshizumi, M. (2006) Tetrahydrobiopterin improves aging-related impairment of endothelium-dependent vasodilation through increase in nitric oxide production. Atherosclerosis, 186, 390-395.
117. McDowell, I. F. and Lang, D. (2000) Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J. Nutr., 130, 369S-372S.
118. Weiss, N. (2005) Mechanisms of increased vascular oxidant stress in hyperhomocys-teinemia and its impact on endothelial function. Curr. Drug. Metab., 6, 27-36.
119. Schnyder, G., Roffi, M., Pin, R., Flammer, Y., Lange, H., Eberli, F. R., Meier, B., Turi, Z. G. and Hess, O. M. (2001) Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N. Engl. J. Med., 345, 1593-1600.
120. Moens, A. L., Claeys, M. J., Wuyts, F. L., Goovaerts, I., Van Hertbruggen, B. S. E., Luc, R. N. C.,Wendelen, B. S., Van Hoof, V. O. and Vrints, C. J. (2007) Effect of Folic Acid on Endothelial Function Following Acute Myocardial Infarction. Am. J. Cardiol., 99, 476-481.
121. Delfino, V. D. A., Vianna, A. C. A., Mocelin, A. J., Barbosa, D. S., Mise, R. A. and Matsuo, T. (2007) Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients. Nutrition, 23, 242-247.
122. Clarke, Z. L., Moat, S. J., Miller, A. L., Randall, M. D., Lewis, M. J. and Lang, D. (2006) Differential effects of low and high dose folic acid on endothelial dysfunction in a murine model of mild hyperhomocysteinaemia. Eur. J. Pharmacol., 551, 92-97.
123. Laight, D. W., Carrier, M. J. and Anggard, E. E. (2000) Antioxidants, diabetes and endothelial dysfunction. Cardiovasc. Res., 47, 457-464.
124. Jariyapongskul, A., Rungjaroen, T., Kasetsuwan, N., Patumraj, S., Seki, J. and Niimi, H. (2007) Long-term effects of oral vitamin C supplementation on the endothelial dysfunction in the iris microvessels of diabetic rats. Microvasc. Res., 74, 32-38.
125. Heitzer, T., Just, H. and Munzel, T. (1996) Antioxidant Vitamin C Improves Endothelial Dysfunction in Chronic Smokers. Circulation, 94, 6-9.
126. Böhm, F., Settergren, M. and Pernow, J. (2007) Vitamin C blocks vascular dysfunction and release of interleukin-6 induced by endothelin-1 in humans in vivo. Atherosclerosis, 190, 408-415.
127. Wu, F., Schuster, D. P., Tyml, K. and Wilson, J. X. (2007) Ascorbate inhibits NADPH oxidase subunit p47phox expression in microvascular endothelial cells. Free Radic. Biol. Med., 42, 124-131.
128. Ting, H. H., Timimi, F. K., Boles, K. S., Creager, S. J., Ganz, P. and Creager, M. A. (1996) Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest., 97, 22-28.
129. Chambers, J. C., McGregor, A., Jean-Marie, J., Obeid, O. A. and Kooner, J. S. (1999) Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia an effect reversible with vitamin C therapy. Circulation, 99, 1156-1160.
130. Navab, M., Imes, S. S., Hama, S. Y., Hough, G. P., Ross, L. A., Bork, R.W., Valente, A. J., Berliner, J. A., Drinkwater, D. C. and Laks, H. (1991) Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest., 88, 2039-2046.
131. Neunteufl, T., Priglinger, U., Heher, S., Zehetgruber, M., Söregi, G., Lehr, S., Huber, K., Maurer, G., Weidinger, F. and Kostner, K. (2000) Effects of Vitamin E on Chronic and Acute Endothelial Dysfunction in Smokers. J. Am. Coll. Cardiol., 35, 277-283.
132. Duffy, S. J., Keaney, J. F., Holbrrook, M., Gokce, N., Swerdloff, P. L., Frei, B., Joseph, A. and Vita, J. A. (2001) Short and long term black tea consumtion reverses endothelial dysfunction in patients with artery diseases. Circulation, 104, 151-156.
133. Squadrito, F., Altavilla, D., Squadrito, G., Saitta, A., Cucinotta, D., Minutoli, L., Deodato, B., Ferlito, M. Campo, G. M., Bova, A. and Caputi, A. P. (2000) Genistein supplementation and estrogen replacement therapy improve endothelial dysfunction induced by ovariectomy in rats. Cardiovasc. Res., 45, 454-462.
134. Ashraf, M. Z., Hussainb, M. E. and Fahim, M. (2005) Antiatherosclerotic effects of dietary supplementations of garlic and turmeric: Restoration of endothelial function in rats. Life Sci., 77, 837-857.
135. Anselm, E., Chataigneau, M., Ndiaye, M., Chataigneau, T. and Schini-Kerth, V. B. (2007) Grape juice causes endothelium-dependent relaxation via a redox-sensitive Src- and Akt-dependent activation of eNOS. Cardiovasc. Res., 73, 404-413.
136. Zhang, B., Hu, S., Qiu, L., Zhu, J., Xie, X., Sun, J., Zhu, Z., Xia, Q. and Bian, K. (2007) Effects of Astragalus membranaceus and its main components on the acute phase endothelial dysfunction induced by homocysteine. Vascul. Pharmacol., 46, 278-285.
137. Vitor, R. F., Mota-Filipe, H., Teixeira, G., Borges, C., Rodrigues, A. I., Teixeira, A. and Paulo, A. (2004) Flavonoids of an extract of Pterospartum tridentatum showing endothelial protection against oxidative injury. J. Ethnopharmacol., 93, 363-370.
138. Lohn, M., Steioff, K., Bleich, M., Busch, A. E. and Ivashchenko, Y. (2005) Inhibition of Rho-kinase stimulatesnitric-oxide independent vasorelaxation. Eur. J. Pharmacol., 507, 179-186.
139. Budzyn, K., Marley, P. D. and Sobey, C. G. (2006) Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol. Sci., 27, 97-104.
140. Shah, D. I. and Singh, M. (2006a) Involvement of Rho-kinase in experimental vascular endothelial dysfunction. Mol. Cell. Biochem., 283, 191-199.
141. Soriano, F. G., Virág, L., Jagtap, P., Szabó, E., Mabley, J. G., Liaudet, L., Marton,A., Hoyt, D. G., Murthy, K. G. K., Salzman, A. L., Southan, G. J. and Szabó, C. (2001) Diabetic endothelial dysfunction: the role of poly (ADP-ribose) polymerase activation. Nat. Med., 7, 108-113.
142. Tasatargil, A., Sadan, G. and Karasu, E. (2007) Homocysteine-induced changes in vascular reactivity of guinea-pig pulmonary arteries: Role of the oxidative stress and poly (ADP-ribose) polymerase activation. Pulm. Pharmacol. Ther., 20, 265-272.
143. Pacher, P., Mabley, J. G., Soriano, F. G., Liaudet, L., Komjati, K. and Szabo, C. (2002) Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation. Br. J. Pharmacol., 135, 1347-1350.
144. Pacher, P., Mabley, J. G., Soriano, F. G., Liaudet, L. and Szabó, C. (2002) Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int. J. Mol. Med., 9, 659-664.
145. Tasatargil, A., Dalaklioglu, S. and Sadan, G. (2004) Poly (ADP-ribose) polymerase inhibition prevents homocysteine-induced endothelial dysfunction in the isolated rat aorta. Pharmacology, 72, 99-105.
146. Radovits, T., Seres, L., Gero, D., Berger, I., Szabó, C., Karck, M. and Szabó, G. (2007) Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction. Exp. Gerontol., 42, 676-685.
147. Boo, Y. C. and Jo, H. (2003) Flow-dependent regulation of endothelial nitric oxide synthase: role of protein kinase. Am. J. Physiol. Cell Physiol., 285, C499-C508.
148. Iaccarino, G., Ciccarelli, M., Sorriento, D., Cipolletta, E., Cerullo, V., Iovino, G. L., Paudice, A., Elia, A., Santulli, G., Campanile, A., Arcucci, O., Pastore, L., Salvatore, F., Condorelli, G. and Trimarco, B. (2004) AKT Participates in Endothelial Dysfunction in Hypertension. Circulation, 109, 2587-2593.
149. Shah, D. I and Singh, M. (2007) Effect of demethylasterriquinone b1 in hypertension associated vascular endothelial dysfunction. Int. J. Cardiol., 120, 317-324.
150. Shah, D. I. and Singh, M. (2006) Possible role of Akt to improve vascular endothelial dysfunction in diabetic and hyperhomocysteinemic rats. Mol. Cell. Biochem., 295, 65-74.
151. Papapetropoulos, A., Fulton, D., Lin, M. I., Fontana, J., McCabe, T. J., Zoellner, S., Garcia-Cardena, G., Zhou, Z., Gratton, J. P. and Sessa, W. C. (2004) Vanadate is a potent activator of endothelial nitric oxide synthase: evidence for the role of serine/threonine kinase Akt and 90-kDa heat shock protein. Mol. Pharmacol., 65, 407-415.
152. Gao, N., Ding, M., Zheng, J. Z., Zhang, A., Leonard, S. S., Liu, K. J., Shi, X. and Jiang, B. H. (2002) Vanadate-induced expression of hypoxia inducible factor 1-alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J. Biol. Chem., 277, 31963-31971.
153. Shah, D. I. and Singh, M. (2006c) Inhibition of protein tyrosin phosphatase improves vascular endothelial dysfunction. Vascul. Pharmacol., 44, 177-182.
154. Zuckerbraun, B. S., Barbato, J. E., Hamilton, A., Sebti, S. and Tzeng, E. (2005) Inhibition of geranylgeranyltransferase I decreases generation of vascular reactive oxygen species and increases vascular nitric oxide production. J. Surg. Res., 124, 256-263.
155. Gadau, S., Emanueli, C., Linthout, S. V., Graiani, G., Todaro, M., Meloni, M., Campesi, I., Ivernici, G., Spillmann, F., Ward, K. and Madeddu, P. (2006) Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia, 49, 405-420.
156. Stirban, A., Negrean, M., Stratmann, B., Gawlowski, T., Horstmann, T., Götting, C., Kleesiek, K., Mueller-Roesel, M., Koschinsky, T., Uribarri, J., Vlassara, H. and Tschoepe, D. (2006) Benfotiamine prevents macro and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care, 29, 2064-2071.
157. Boo, Y. C., Hwang, J., Sykes, M., Michell, B. J., Kemp, B. E., Lum, H. and Jo, H. (2002) Shear stress stimulates phosphorylation of eNOS at Ser (635) by a protein kinase A-dependent mechanism. Am. J. Physiol. Heart Circ. Physiol., 283, H1819-H1828.
158. Qiao, J., Huang, F. and Lum, H. (2003) PKA inhibits RhoA activation: a protection mechanism against endothelial barrier dysfunction. Am. J. Physiol. Lung Cell. Mol. Physiol., 284, L972-L980.
159. Shah, D. I. and Singh, M. (2006) Possible role of exogenous cAMP to improve vascular endothelial dysfunction in hypertensive rats. Fundam. Clin. Pharmacol., 20, 595-604.
160. Shah, D. I. and Singh, M. (2006) Activaction of protein kinase A improves vascular endothelial dysfunction. Endothelium, 13, 267-277.